Sun Sentinel Palm Beach Edition
Gilead says remdesivir helps some patients
A California biotech company says its experimental drug remdesivir improved symptoms when given for five days to moderately ill, hospitalized patients with COVID-19.
Gilead Sciences gave few details Monday but said full results would be published.
Remdesivir is the only treatment shown in a rigorous experiment to help fight the coronavirus.
A large study led by the National Institutes of Health recently found it could shorten average recovery time from 15 days to 11 days in hospitalized patients with severe disease.
The drug is given via IV and is designed to interfere with an enzyme the virus uses to copy its genetic material.
It’s approved for treating COVID-19 in Japan and is authorized for emergency use in the United States in some patients.
The study involved nearly 600 patients who had moderate pneumonia but did not need oxygen. All were randomly assigned to get five or 10 days of the drug plus standard care, or standard care alone. Patients and their doctors knew who was getting what, which limits the objectivity of the results.
By the 11th day, those on five days of remdesivir were 65% more likely to improve by at least one on a sevenpoint scale that included measures such as needing treatment with a breathing machine, Gilead said.
Ten days of treatment did not prove better than standard care alone.
There were no deaths among patients on five days of the drug, two among those on 10 days, and four among patients getting standard care alone.
“There was a control group which does help verify that remdesivir has some benefits,” said Dr. Radha Rajasingham, an infectious disease specialist at the University of Minnesota Medical Center who had no role in the work.